OLD National Bancorp IN Cuts Holdings in Danaher Co. (NYSE:DHR)

OLD National Bancorp IN lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 0.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,685 shares of the conglomerate’s stock after selling 631 shares during the period. OLD National Bancorp IN’s holdings in Danaher were worth $17,910,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Danaher by 20.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after acquiring an additional 1,533 shares during the period. Cercano Management LLC increased its position in shares of Danaher by 11.4% in the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after buying an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after buying an additional 96,395 shares during the last quarter. Donaldson Capital Management LLC raised its stake in shares of Danaher by 5.8% during the 1st quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock worth $367,000 after buying an additional 80 shares during the last quarter. Finally, Caden Capital Partners LP boosted its position in shares of Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. The Goldman Sachs Group raised their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. SVB Leerink upped their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Bank of America raised their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold a total of 66,797 shares of company stock worth $18,039,944 in the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Down 0.2 %

Danaher stock traded down $0.52 during trading on Friday, reaching $268.12. The company had a trading volume of 2,017,765 shares, compared to its average volume of 2,898,902. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $198.59 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 4.62 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The stock’s 50 day moving average price is $257.31 and its two-hundred day moving average price is $252.14.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company earned $2.05 EPS. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. As a group, equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.